Neumora Therapeutics (NASDAQ:NMRA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Neumora Therapeutics (NASDAQ:NMRA) from a strong sell rating to a sell rating in a research note released on Saturday.

Other analysts also recently issued research reports about the company. Needham & Company LLC cut their price target on Neumora Therapeutics from $8.00 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday, June 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neumora Therapeutics in a research note on Friday, July 17th. HC Wainwright reissued a “buy” rating on shares of Neumora Therapeutics in a report on Tuesday, July 28th. Mizuho cut their target price on Neumora Therapeutics from $6.00 to $4.00 and set an “outperform” rating on the stock in a research note on Thursday, June 18th. Finally, Royal Bank Of Canada reduced their price target on Neumora Therapeutics from $7.00 to $5.00 and set an “outperform” rating for the company in a report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $6.57.

Neumora Therapeutics Trading Down 5.0%

NASDAQ:NMRA opened at $1.52 on Friday. The firm has a market capitalization of $281.63 million, a P/E ratio of -1.24 and a beta of 2.75. The company has a debt-to-equity ratio of 0.75, a current ratio of 5.09 and a quick ratio of 5.09. Neumora Therapeutics has a one year low of $0.83 and a one year high of $3.65. The company’s 50-day simple moving average is $1.61 and its 200 day simple moving average is $2.12.

Neumora Therapeutics (NASDAQ:NMRA) last announced its earnings results on Friday, August 14th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01. As a group, analysts forecast that Neumora Therapeutics will post -0.93 EPS for the current fiscal year.

Institutional Investors Weigh In On Neumora Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. HBK Sorce Advisory LLC purchased a new position in Neumora Therapeutics in the 2nd quarter worth approximately $26,000. Hsbc Holdings PLC purchased a new stake in Neumora Therapeutics during the 4th quarter valued at $27,000. Virtu Financial LLC bought a new stake in shares of Neumora Therapeutics in the 3rd quarter worth $31,000. Fred Alger Management LLC bought a new stake in shares of Neumora Therapeutics in the 4th quarter worth $40,000. Finally, Canada Pension Plan Investment Board bought a new stake in shares of Neumora Therapeutics in the 2nd quarter worth $41,000. Institutional investors own 47.65% of the company’s stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.